4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
1 citations
,
October 2014 in “Annals of oncology” Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
8 citations
,
June 2022 in “Cancers” Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.
July 2022 in “Journal of Investigative Dermatology” 2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
February 2025 in “Chemico-Biological Interactions” 5-Fluorouracil causes hair loss by blocking signals needed for hair growth.
2 citations
,
January 2025 in “Journal of Clinical Immunology” 1 citations
,
January 2017 in “International journal of trichology” Diphenylcyclopropenone (DPCP) effectively treated both alopecia areata and verruca vulgaris.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
54 citations
,
June 2023 in “International Journal of Molecular Sciences” Myricetin shows promise as an anticancer agent by reducing inflammation and enhancing drug effectiveness.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
19 citations
,
November 2018 in “Nutrients” Annurca apple extract may protect mouse hair from damage by chemotherapy and could help treat hair loss without promoting cancer growth.
February 2024 in “Indian Journal of Chemistry” Compound N4 effectively kills breast cancer cells and compounds N2 and N3 have strong antibacterial and antifungal properties.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
August 2024 in “Postgraduate Medical Journal” A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
5 citations
,
June 2012 in “The journal of investigative dermatology/Journal of investigative dermatology” Putting thymidine dinucleotide on newborn mice's skin can delay and reduce skin cancer.
16 citations
,
January 2000 in “Journal of dermatological treatment” Calcipotriol scalp solution works better than coal tar shampoo for treating scalp psoriasis and is safe for long-term use.
1 citations
,
December 2019 in “World rabbit science” High doses of cobalt stopped hair growth in rabbits.
2 citations
,
December 2013 in “Cancer Research” Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.
January 2026 in “Journal of Ethnopharmacology” Cedrol promotes hair growth better than baricitinib by regulating immune cells.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
26 citations
,
November 2016 in “European Journal of Clinical Pharmacology” Valproic acid helps delay hair loss and increases survival time for high-grade glioma patients undergoing radiation therapy.
51 citations
,
May 2008 in “Mycoses” Terbinafine HCl nail solutions with DDAIP HCl are more effective than current treatments for nail infections.